Glitin tablet: Each coated tablet contains Linagliptin INN 5 mg.
Glitin is a preparation of Linagliptin. It is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Linagliptin increases the concentrations of active incretin hormones and stimulates the release of Insulin in a glucose dependent manner and decreases the level of glucagon in the circulation and thus regulates the glucose homeostasis. incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase Insulin biosynthesis and secretion from pancreatic beta-cells in the presence of elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha-cells, resulting in a reduction in hepatic glucose output.
The recommended dose of Glitin ® is 5 mg once daily and can be taken with or without food. If added with Metformin, the dose of Metformin should be maintained and Linagliptin administered concomitantly. When used in combination with Sulfonylurea, or with Insulin, a lower dose of Sulfonylurea or Insulin may be considered to reduce the risk of hypoglycemia.
No dosage adjustment is required for hepatic or renal impaired patients.
Pediatric patients: Safety and effectiveness of Linagliptin in patients below the age of 18 have not been established.
Sulfonylureas and insulin increase hypoglycemic risk; ACE inhibitors increase risk of angioedema; thiazide diuretics reduce antidiabetic effect.
Linagliptin is contraindicated in patient with a history of hypersensitivity to Linagliptin or any of excipients.
Common: Nasopharyngitis, sore throat, hypoglycemia (with insulin/sulfonylurea), muscle pain. Rare: Pancreatitis, angioedema, urticaria.
Overdose
During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose related clinical adverse drug reactions, There is no experience with doses above 600 mg in humans.
Category B. No adequate and well-controlled studies in pregnant women; use only if potential benefit justifies fetal risk. Lactation: Caution should be exercised when administered to a nursing woman.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep away from the reach of children.